Advertisement

Current Rheumatology Reports

, Volume 14, Issue 2, pp 121–129 | Cite as

Pediatric Vasculitis

  • Ezgi Deniz Batu
  • Seza Ozen
PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Abstract

The primary systemic vasculitides in childhood are quite rare except for Henoch-Schönlein purpura and Kawasaki disease. These are usually self-limited diseases. The etiopathogenesis for most of them is not clearly understood. However, it is usually thought that environmental triggers (mostly infectious) evoke an aggravated inflammatory response in susceptible individuals. The classification criteria for most of them were recently validated for children. Clinical manifestations are determined by the organs affected, reflecting the involved vessels on a background of constitutional symptoms. For treatment, the main data are adapted from adult studies, especially for rarer vasculitides in childhood. In this review, the recent classification criteria, current pathophysiologic pathways, and treatment protocols are summarized.

Keywords

Vasculitis Child Henoch-Schönlein purpura Behçet’s syndrome Pediatric Vasculitis Kawasaki disease Takayasu’s arteritis ANCA-associated vasculitis Polyarteritis nodosa Cutaneous polyarteritis nodosa 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep. 2000;2:411–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Rowley AH, Ozen S, Sundel RP, et al. A clinician’s pearls and myths in rheumatology. London: Springer; 2009. p. 219–29.CrossRefGoogle Scholar
  3. 3.
    Ozen S. Problems in classifying vasculitis in children. Pediatr Nephrol. 2005;20:1214–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterization. Ann Rheum Dis. 2010;69:790–7.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Ozen S, Pistoiro A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798–806. This is the criteria validation for most of the vasculitides in childhood. PubMedCrossRefGoogle Scholar
  6. 6.
    Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children. Am J Dis Child. 1960;99:833–54.Google Scholar
  8. 8.
    Gedalia A. Henoch-Schönlein purpura. Curr Rheumatol Rep. 2004;6:195–202.PubMedCrossRefGoogle Scholar
  9. 9.
    Saulsbury FT. Epidemiology of Henoch-Schönlein purpura. Cleve Clin J Med. 2002;69:SII87–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007;22:2067–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Kawasaki Y, Suyama K, Yugeta E, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima prefecture, Japan. Int Urol Nephrol. 2010;42:1023–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawasaki Y. The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis. Clin Exp Nephrol 2011, In press.Google Scholar
  13. 13.
    Shin JI, Song KS, Kim H, et al. The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. Br Assoc Dermatol. 2011;164:1348–55.CrossRefGoogle Scholar
  14. 14.
    Chen T, Guo Z-P, Li M-M, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schönlein purpura. Clinical and Experimental Immunology 2011, In press.Google Scholar
  15. 15.
    Brogan P, Bagga A. Leukocytoclastic vasculitis. In: Cassidy JT, Petty RE, Laxer RM, et al., editors. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011. p. 482–97.Google Scholar
  16. 16.
    Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schönlein purpura: a review article. South Med J. 2007;100(8):821–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen S-Y, Kong M-S. Gastrointestinal manifestations and complications of Henoch-Schönlein purpura. Chang Gung Med. 2004;27:175–81.Google Scholar
  18. 18.
    Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007;369(9566):976–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15(2):99–138.PubMedCrossRefGoogle Scholar
  21. 21.
    Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol. 2002;16(3):411–25.PubMedGoogle Scholar
  22. 22.
    •• Davin J-C. Henoch-Schönlein purpura nephritis: pathophysiology, treatment and future strategy. Clin J Am Soc Nephrol. 2011;6:679–89. This is an excellent review describing the treatment strategies on pathogenetic pathways in HSP. PubMedCrossRefGoogle Scholar
  23. 23.
    Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schönlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49(1):9–14.PubMedGoogle Scholar
  24. 24.
    Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Schönlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Goldstein AR, White RHR, Akuse R, et al. Long term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Wakaki H, Ishikura K, Hataya H, et al. Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr. 2004;163:285–91.PubMedCrossRefGoogle Scholar
  28. 28.
    De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301–8.PubMedGoogle Scholar
  29. 29.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Yanagawa H, Nakamura Y, Kawasaki T, et al. Nationwide epidemics of Kawasaki disease in Japan during winter of 1985–86. Lancet. 1986;2(8516):1138–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Burgner D, Davilla S, Breunis WB, et al. International Kawasaki Disease Genetic Consortium: a genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PloS Genet. 2009;5(1):e1000319.PubMedCrossRefGoogle Scholar
  33. 33.
    Oh JH, Han JW, Lee SJ, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol. 2008;29:402–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Hsieh Y-Y, Lin Y-J, Chang C-C, et al. Human lymphocyte antigen B-associated transcripts 2,3 and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal. 2010;24:262–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009;168:157–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Levy M, Karen G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J. 1990;9:122–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Pinna GS, Kafetzis DA, Tselkas OI, et al. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263–70.PubMedCrossRefGoogle Scholar
  38. 38.
    Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9:441–8.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;In press. This is the most recent review defining clearly the challenges in KD. Google Scholar
  40. 40.
    Tse SM, Silverman ED, Mc Crindle BW, et al. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002;140:450–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29:398–401.PubMedCrossRefGoogle Scholar
  42. 42.
    Furukawa T, Kishiro M, Akimoto M, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93:142–6.PubMedCrossRefGoogle Scholar
  43. 43.
    McCrindle BW. Kawasaki disease: a childhood disease with important consequences into adulthood. Circulation. 2009;120:6–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Ozen S, Bakkaloglu A, Dusunsel R, et al. Childhood vasculitis in Turkey: a nationwide survey. Clin Rheumatol. 2007;26:196–200.PubMedGoogle Scholar
  45. 45.
    Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa associated with familial mediterranean fever: is it an association? Semin Arthritis Rheu. 2001;30:281–7.CrossRefGoogle Scholar
  47. 47.
    Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166:145–51.PubMedCrossRefGoogle Scholar
  48. 48.
    Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–11.PubMedCrossRefGoogle Scholar
  49. 49.
    Dillon MJ, Eleftherious D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25:1641–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Dillon MJ. Vasculitis treatment: new therapeutic approaches. Eur J Pediatr. 2006;165:351–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRefGoogle Scholar
  52. 52.
    Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int. 2011;In press.Google Scholar
  53. 53.
    Fathalla BM, Miller L, Brady S, et al. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol. 2005;53:724–8.PubMedCrossRefGoogle Scholar
  54. 54.
    David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69:685–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005;38:93–103.PubMedCrossRefGoogle Scholar
  56. 56.
    Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.PubMedCrossRefGoogle Scholar
  57. 57.
    Vamvakopoulos J, Savage CO, Harper L. ANCA-associated vasculitides—lessons from the adult literature. Pediatr Nephrol. 2010;25:1397–407.PubMedCrossRefGoogle Scholar
  58. 58.
    Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patient. Semin Arthritis Rheum. 2008;39:108–15.PubMedCrossRefGoogle Scholar
  59. 59.
    Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis & Rheumatism. 2007;52(5):837–44.CrossRefGoogle Scholar
  60. 60.
    Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205–12.PubMedCrossRefGoogle Scholar
  61. 61.
    Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–29.PubMedGoogle Scholar
  62. 62.
    Sharma BK, Sagar S, Chugh KS, et al. Spectrum of renovascular hypertension in the young in north India. Angiology. 1985;36:370–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Vanoli M, Daina E, Salvarini C, et al. Takayasu arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Hahn D, Thomson PD, Kala U, et al. A review of Takayasu’s arteritis in children in Gauteng, South Africa. Pediatr Nephrology. 1998;12:668–75.CrossRefGoogle Scholar
  66. 66.
    •• Morishita KA, Rosendahl K, Brogan P. Familial Takayasu arteritis—a pediatric case and a review of the literature. Pediatr Rheum. 2011;In press. This is a recent review of familial TA cases in the literature encouraging the search for candidate genes in TA pathogenesis. Google Scholar
  67. 67.
    Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913–9.PubMedGoogle Scholar
  68. 68.
    Yamada I, Nakagawa T, Himero Y, et al. Takayasu arteritis: diagnosis with breath hold contrast enhanced 3-dimensional MR angiography. J Magn Reson Imaging. 2000;II:481–7.CrossRefGoogle Scholar
  69. 69.
    Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am. 2006;32:173–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;12:16–24.CrossRefGoogle Scholar
  72. 72.
    Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: analysis of 204 Korean patients at a single center. Int J Cardiol. 2011;In press.Google Scholar
  73. 73.
    Ozen S. The ‘other’ vasculitic syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58:3951–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum. 2009;61:600–4.PubMedCrossRefGoogle Scholar
  76. 76.
    •• Ozen S. Pediatric onset Behçet disease. Curr Opin Rheumatol. 2010;22:585–89. This is a recent review of childhood Behçet’s syndrome. PubMedCrossRefGoogle Scholar
  77. 77.
    • Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study. Arthritis Res Ther. 2009;11:R66. This was the first GWAS in Behçet’s syndrome. PubMedCrossRefGoogle Scholar
  78. 78.
    Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedCrossRefGoogle Scholar
  79. 79.
    International Study Group for Behcet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.Google Scholar
  80. 80.
    Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee, EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62.PubMedCrossRefGoogle Scholar
  81. 81.
    Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol. 2009;22:551–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of PediatricsHacettepe University Children’s HospitalAnkaraTurkey
  2. 2.Department of Pediatric RheumatologyHacettepe UniversityAnkaraTurkey

Personalised recommendations